Recent studies of unrelated donor (UD) stem cell transplantation for acquired severe aplastic anemia.
| Reference . | Year of Transplants . | n . | Graft Rejection . | Acute GVHD II-IV/III-IV . | Chronic GVHD All/extensive . | Survival . | Regimen . |
|---|---|---|---|---|---|---|---|
| Abbreviations: GVHD, graft-versus-host disease; MUD, matched unrelated donor; M/M, mis-matched; CY, cyclophosphamide; ATG, antithymocyte globulin; TBI, total body irradiation; TLI, total lymphocyte infusion; PBSC, peripheral blood stem cell; UCB, umbilical cord blood; NK, not known | |||||||
| Passweg 2006 | 1988–1998 | 181 (MUD) | 17% | 48%/NK | 29%/NK | 39% at 5 yr | CY ± irradiation ± antibodies |
| 51 (M/M) | 51% | 37%/NK | 24%/NK | 36% at 5 yr | |||
| Kojima 2002 | 1993–2000 | 154 | 11% | 29%/20% | 30%/15% | 60% at 5 yr for A,B,DRB1 matches | CY (120–200 mg/kg), irradiation ± ATG |
| 79 (MUD), 75 (M/M) | |||||||
| Deeg 2006 | 1994–2004 | 62 (MUD) | 2% (MUD) | 69%/NK (MUD) | 52%/NK (MUD) | 61% at 5 yr (MUD) | CY 200 mg/kg, ATG, low dose TBI (2–6 Gy). If ATG-intolerant, CY 120 mg/kg, TBI 12Gy. |
| 25 (M/M) | 11% (M/M) | 77%/NK (M/M) | 57%/NK (M/M) | 40% (M/M) | |||
| Bacigalupo 2005 | 1998–2004 | 38 | 18% | 27%/6% | 27%/6% | 73% at 5 yr | Fludarabine 120 mg/m2, CY 1200 mg/m2, ATG |
| 28 (MUD), | |||||||
| 10 (M/M: | |||||||
| 5 UD, 5 family) | |||||||
| Benesch 2004 | NK | 8 (4 MUD) | 0 | 0 | 0 | 8/8 alive | CY ± ATG ± anti-CD3 ± Thiotepa ± TLI ± Fludarabine ± Busulphan, with CD34+-selected PBSC |
| Mao 2005 | 1998–2004 | 9 | 22% | 0 | 28%/0 | 7/9 alive | CY 60 mg/kg, ATG, UCB transplants in adults |
| Reference . | Year of Transplants . | n . | Graft Rejection . | Acute GVHD II-IV/III-IV . | Chronic GVHD All/extensive . | Survival . | Regimen . |
|---|---|---|---|---|---|---|---|
| Abbreviations: GVHD, graft-versus-host disease; MUD, matched unrelated donor; M/M, mis-matched; CY, cyclophosphamide; ATG, antithymocyte globulin; TBI, total body irradiation; TLI, total lymphocyte infusion; PBSC, peripheral blood stem cell; UCB, umbilical cord blood; NK, not known | |||||||
| Passweg 2006 | 1988–1998 | 181 (MUD) | 17% | 48%/NK | 29%/NK | 39% at 5 yr | CY ± irradiation ± antibodies |
| 51 (M/M) | 51% | 37%/NK | 24%/NK | 36% at 5 yr | |||
| Kojima 2002 | 1993–2000 | 154 | 11% | 29%/20% | 30%/15% | 60% at 5 yr for A,B,DRB1 matches | CY (120–200 mg/kg), irradiation ± ATG |
| 79 (MUD), 75 (M/M) | |||||||
| Deeg 2006 | 1994–2004 | 62 (MUD) | 2% (MUD) | 69%/NK (MUD) | 52%/NK (MUD) | 61% at 5 yr (MUD) | CY 200 mg/kg, ATG, low dose TBI (2–6 Gy). If ATG-intolerant, CY 120 mg/kg, TBI 12Gy. |
| 25 (M/M) | 11% (M/M) | 77%/NK (M/M) | 57%/NK (M/M) | 40% (M/M) | |||
| Bacigalupo 2005 | 1998–2004 | 38 | 18% | 27%/6% | 27%/6% | 73% at 5 yr | Fludarabine 120 mg/m2, CY 1200 mg/m2, ATG |
| 28 (MUD), | |||||||
| 10 (M/M: | |||||||
| 5 UD, 5 family) | |||||||
| Benesch 2004 | NK | 8 (4 MUD) | 0 | 0 | 0 | 8/8 alive | CY ± ATG ± anti-CD3 ± Thiotepa ± TLI ± Fludarabine ± Busulphan, with CD34+-selected PBSC |
| Mao 2005 | 1998–2004 | 9 | 22% | 0 | 28%/0 | 7/9 alive | CY 60 mg/kg, ATG, UCB transplants in adults |